Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies using goat-milk exosomes to improve delivery and patient access.

Bio-Sourcing and Tiny Cargo have entered a strategic collaboration to develop oral monoclonal antibody (mAb) therapies using milk-derived extracellular vesicles, including exosomes.

The partnership brings together Bio-Sourcing’s platform for producing monoclonal antibodies in goat milk with Tiny Cargo’s technology for isolating and loading milk-derived exosomes. The companies aim to evaluate whether combining antibody production and delivery systems from the same biological source can support oral administration of biologics.

Monoclonal antibodies are typically delivered via injection due to degradation in the gastrointestinal tract. Both companies are exploring whether milk-derived exosomes, which are naturally adapted to survive digestion, could enable antibodies to reach the bloodstream when taken orally.

Bio-Sourcing’s approach uses a specific breed of goats to produce monoclonal antibodies in milk at scale. The same process also generates extracellular vesicles, which can be used as delivery vehicles. The company says this approach may offer cost and scalability advantages compared to traditional bioreactor-based manufacturing.

Tiny Cargo has developed a manufacturing platform designed to isolate and load exosomes with therapeutic payloads. The company is focusing on pharmaceutical-grade production of milk-derived vesicles for drug delivery applications.

Together, the companies will combine these capabilities to test oral delivery of monoclonal antibodies, an area where no approved therapies currently exist.

Bertrand Mérot, CEO of Bio-Sourcing, said: “With Tiny Cargo, we’re pairing two outstanding product platforms — Bio-Sourcing’s high-yield, sustainable goat-milk manufacturing of monoclonal antibodies and milk EVs with Tiny Cargo’s industrial-scale milk exosome isolation and loading — to unlock true oral delivery for biologics.”

Alan Gourdie, CEO of Tiny Cargo, added: “Milk-derived exosomes are among the most resilient delivery systems in nature. The ability to source both the antibody and the delivery vehicle from the same biological starting point is a rare and powerful advantage.”

The companies will initially focus on evaluating therapeutic applications via the oral route, with the aim of improving patient access to biologics and reducing reliance on injectable treatments.

While early-stage, the collaboration reflects growing interest in alternative delivery systems for biologics, particularly approaches that could simplify administration and expand access.